Arthur Tzianabos's Insider Trades & SAST Disclosures
Arthur Tzianabos's most recent trade in Stoke Therapeutics Inc was a trade of 122,651 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Arthur Tzianabos.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director, Interim Executive Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 122,651 | 122,651 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 25,674 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Tzianabos O. Arthur | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 25,674 | 25,674 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Tzianabos O. Arthur | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur Tzianabos O. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 1,095 | 8,248 | - | - | Common Stock | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 1,095 | 0 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 25 Mar 2024 | 265 | 7,983 | - | 24.2 | 6,413 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 31,739 | 0 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 13 Feb 2024 | 31,739 | 31,739 (0%) | 0% | 2.2 | 69,508 | Common Stock |
| Q32 Bio Inc. | Tzianabos O. Arthur | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 19,140 | 141,815 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | Tzianabos O. Arthur | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 19,140 | 19,720 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | O. Arthur Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 14,280 | 0 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 14,280 | 122,675 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | Arthur Tzianabos O. | Director | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 01 Jan 2024 | 13,037 | 128,778 (0%) | 0% | 0.6 | 7,445 | Common Stock |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 09 Jan 2023 | 10,616 | 108,395 (0%) | 0% | 1.4 | 14,762 | Common Stock |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 19,140 | 38,860 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 19,140 | 119,011 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 13,860 | 99,871 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 13,860 | 14,280 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 350,000 | 350,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 58,000 | 58,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 13,860 | 28,140 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 13,860 | 91,365 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 5,354 | 86,011 (0%) | 0% | 3.8 | 20,239 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2021 | 10,000 | 13,447 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 60.67 per share. | 19 Feb 2021 | 10,000 | 0 (0%) | 0% | 60.7 | 606,652 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 19 Feb 2021 | 10,000 | 10,000 (0%) | 0% | 2.2 | 21,900 | Common Stock |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 254,000 | 254,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 42,000 | 42,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 20,000 | 23,447 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 23 Nov 2020 | 20,000 | 20,000 (0%) | 0% | 2.2 | 43,800 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.97 per share. | 23 Nov 2020 | 10,196 | 5,504 (0%) | 0% | 46.0 | 468,720 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 46.85 per share. | 23 Nov 2020 | 5,294 | 210 (0%) | 0% | 46.8 | 248,009 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.08 per share. | 23 Nov 2020 | 4,300 | 15,700 (0%) | 0% | 45.1 | 193,838 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 47.61 per share. | 23 Nov 2020 | 210 | 0 (0%) | 0% | 47.6 | 9,998 | Common Stock |
| Stoke Therapeutics Inc | Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges